In February, Fresenius confirmed the sale of its assisted reproduction subsidiary, Eugin Group (Euvitro), to the funds KKR and GED Capital. This acquisition, previously agreed upon in November alongside IVI RMA GLOBAL (a leading assisted reproduction company of KKR), was finalized after obtaining approval from the relevant competition authorities. The operation involves the sale of Eugin Group to KKR and GED Capital, generating revenues of 500 million euros for Fresenius, including profits.
This agreement allows GED Capital to enter the assisted reproduction business and strengthen its healthcare portfolio. GED’s purchase includes 35 clinics in 9 countries, comprising 6 in Europe and 3 in Latin America. The sales of the business acquired by GED are estimated at around 100 million euros.
On the other hand, the American fund KKR, which is a majority stakeholder in the Spanish group IVI RMA, acquired the North American and Canadian business of Eugin.
Eugin Group, owned by the German group Fresenius, is one of the leading global references in assisted reproduction, with operations in 11 countries, 69 clinics, and over 1,700 employees.
The rapid growth of the assisted reproduction sector has attracted the attention of significant international investment funds, reflecting demographic and cultural changes in society.
For GED, this acquisition marks its seventh operation in the GEDVI Spain Fund and the third in the healthcare sector, highlighting its commitment to investing in strategic and high-impact areas. Transaction advisors were King & Wood Mallesons Spain, Kirkland & Ellis DE Karriere, and Freshfields Bruckhaus Deringer.
